BART Sends Bayer’s Trasylol Off The Market
Bayer “temporarily” phases out proteinase inhibitor after top-line data show 50% higher death rate for Trasylol versus comparators.
Bayer “temporarily” phases out proteinase inhibitor after top-line data show 50% higher death rate for Trasylol versus comparators.